Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)‘s stock had its “buy” rating reiterated by equities research analysts at Piper Jaffray Cos. in a research note issued on Thursday. They presently have a $16.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price objective points to a potential upside of 39.13% from the company’s current price.
Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 1.86% during mid-day trading on Thursday, hitting $11.50. The company had a trading volume of 483,830 shares. The firm’s market cap is $496.26 million. The stock’s 50 day moving average price is $11.17 and its 200 day moving average price is $9.28. Vanda Pharmaceuticals has a 52-week low of $6.91 and a 52-week high of $14.50.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.12. The firm had revenue of $36.02 million for the quarter, compared to the consensus estimate of $36.03 million. During the same period in the prior year, the business earned ($0.13) EPS. The company’s quarterly revenue was up 30.6% on a year-over-year basis. On average, equities research analysts predict that Vanda Pharmaceuticals will post ($0.88) EPS for the current fiscal year.
Several hedge funds recently made changes to their positions in VNDA. Boston Advisors LLC increased its stake in shares of Vanda Pharmaceuticals by 0.7% in the second quarter. Boston Advisors LLC now owns 36,190 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 245 shares during the period. Bank of Montreal Can bought a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at about $132,000. Acadian Asset Management LLC increased its stake in shares of Vanda Pharmaceuticals by 1,243.1% in the second quarter. Acadian Asset Management LLC now owns 149,689 shares of the biopharmaceutical company’s stock valued at $1,675,000 after buying an additional 138,544 shares during the period. BNP Paribas Arbitrage SA increased its stake in shares of Vanda Pharmaceuticals by 3.4% in the second quarter. BNP Paribas Arbitrage SA now owns 43,511 shares of the biopharmaceutical company’s stock valued at $487,000 after buying an additional 1,411 shares during the period. Finally, Squarepoint Ops LLC increased its stake in shares of Vanda Pharmaceuticals by 5.3% in the first quarter. Squarepoint Ops LLC now owns 25,600 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 1,300 shares during the period.
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
